A Cross-sectional Study on the Association of Peptidoglycan Fragments Derived From Gut Microbiota With Colorectal Cancer

NCT06379412 | Recruiting

• 1 other identifier: Zhujianghmy
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to explore the association of peptidoglycan fragments derived from gut microbiota with colorectal cancer (CRC). The main question it aims to answer is: Are peptidoglycan fragments from the gut microbiota associated with the progression of colorectal cancer? Participants will provide biological specimens (blood, feces, colon tissue obtained during surgery)

Conditions

Colorectal Cancer

Outcome Measures

Primary Outcomes (1)

• HPLC-MS/MS was used to detect peptidoglycan fragment content in biological specimens of 200 participants

  The content of peptidoglycan fragments was detected by HPLC-MS/MS

  baseline (before treatment)

Study Arms (4)

Colorectal Cancer(CRC)

People who are diagnosed with CRC by colonoscopy and pathological biopsy

Other: observational study, no intervention

Colorectal adenoma(CRA)

People who are diagnosed with CRA by colonoscopy and pathological biopsy

Other: observational study, no intervention

Colorectal polyp(CRP)

People who are diagnosed with CRP by colonoscopy and pathological biopsy

Other: observational study, no intervention

Healthy

People who have no obvious abnormality in the whole colon

Other: observational study, no intervention

Interventions

observational study, no intervention OTHER

observational study, no intervention

Colorectal Cancer(CRC); Colorectal adenoma(CRA); Colorectal polyp(CRP); Healthy

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Meet eligibility criteria

You may qualify if:

• People who underwent total colonoscopy in gastroenteroscopy room.
• People who agree to participate in this study and are willing to sign informed consent.

You may not qualify if:

• Previous diagnosis of malignant tumors other than colorectal cancer.
• Received any of the following drug treatments within 1 month before sample collection: ① Drugs used for the treatment of colorectal diseases; ② Antibiotics; ③probiotics; ④ Laxatives.
• Patients with a family history of colorectal cancer.

Sponsors & Collaborators

• Zhujiang Hospital: lead

Study Sites (1)

Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, 510000, China

RECRUITING

MeSH Terms

Conditions

Colorectal Neoplasms

Interventions

Observation

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Intervention Hierarchy (Ancestors)

Methods; Investigative Techniques

Study Officials

• He Xiaolong, Professor

  Southern Medical University, China

  STUDY DIRECTOR

Central Study Contacts

Hu Mengyao

CONTACT

1587088392; 1377549166@qq.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 18, 2024
• First Posted: April 23, 2024
• Study Start: July 1, 2023
• Primary Completion: December 1, 2024
• Study Completion: December 1, 2024
• Last Updated: April 26, 2024

Record last verified: 2024-04

Locations

CN (1)